Amgen Provides Update On Hurricane Maria

THOUSAND OAKS, Calif., Sept. 25, 2017 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today provided an update on Hurricane Maria's impact on the Company's manufacturing facilities in Puerto Rico. The safety of the more than 2,000 Amgen colleagues and their families on the island remains a top priority for Amgen, and outreach to impacted staff is ongoing. 

http://investors.amgen.com/phoenix.zhtml?c=61656&p=RssLanding&cat=news&id=2302597

Amgen Foundation Pledges Up To $5 Million To Hurricane Maria Relief Efforts

THOUSAND OAKS, Calif., Sept. 22, 2017 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that the Amgen Foundation has pledged $3 million to support urgent Hurricane Maria relief efforts in Puerto Rico. The Foundation also has committed up to an additional $2 million for longer-term rebuilding efforts.  Amgen is also activating its Staff Disaster Relief Fund to aid Amgen staff in Puerto Rico, including financial assistance for shelter, medical attention, clothing and other critical relief.

http://investors.amgen.com/phoenix.zhtml?c=61656&p=RssLanding&cat=news&id=2302400

EVENITY™ (romosozumab) ARCH Study Results Published In The New England Journal Of Medicine

THOUSAND OAKS, Calif. and BRUSSELS, Sept. 11, 2017 /PRNewswire/ -- Amgen (NASDAQ:AMGN) and UCB (Euronext Brussels: UCB) today announced detailed results from the Phase 3 ARCH study showing that 12 months of EVENITY™* (romosozumab) followed by alendronate was superior in reducing new vertebral, clinical, non-vertebral and hip fracture risk in postmenopausal women with osteoporosis at high risk for fracture, compared to alendronate alone. Overall adverse events and serious adverse events were generally similar between the treatment groups with the exception of the previously reported imbalance in positively adjudicated cardiovascular serious adverse events. The results were simultaneously published in the New England Journal of Medicine (NEJM) and presented today as a late-breaking abstract at an oral scientific session at the Annual Meeting of the American Society for Bone Mineral Research (ASBMR) in Denver. 

http://investors.amgen.com/phoenix.zhtml?c=61656&p=RssLanding&cat=news&id=2299800

Amgen To Present At The Bank Of America Merrill Lynch 2017 Health Care Conference

Amgen - Investors - RSS Content

Amgen And Harvard Pilgrim Agree To First Cardiovascular Outcomes-Based Refund Contract For Repatha® (Evolocumab)

Harvard Pilgrim Refines the Utilization Management Criteria to Help High-Risk Cardiovascular Patients Access Repatha First-of-its-Kind Contract Will Demonstrate Value to Harvard Pilgrim Plans for Cardiovascular Patients

Amgen - Investors - RSS Content

Amgen To Participate In The 2017 World Medical Innovation Forum™ Focused On Cardiovascular Disease

Amgen - Investors - RSS Content

Amgen Reports First Quarter 2017 Financial Results

Amgen - Investors - RSS Content

FDA Grants Priority Review For Amgen's BLINCYTO® (blinatumomab) Supplemental Biologics License Application

Application Includes Overall Survival Data From Phase 3 TOWER Study to Support Conversion From Accelerated Approval to Full Approval Acceptance Reinforces Significant Need for Innovative Treatment Options for Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia BLINCYTO is the First-and-Only Approved Bispecific CD19-Directed CD3 T Cell Engager (BiTE®) Immunotherapy

Amgen - Investors - RSS Content

Amgen Awards Three Golden Tickets for LabCentral Residency

CAMBRIDGE, Mass., March 28, 2017 /PRNewswire/ -- Amgen (NASDAQ:AMGN) and LabCentral announced that Cocoon Biotech, Torus Therapeutics, and Holobiome are the winners of Golden Ticket awards. Sponsored by Amgen, the Golden Ticket awards underwrite the cost of a lab bench for a scientist from each organization to reside in LabCentral's open lab for one year. LabCentral is an innovative, shared laboratory space designed as a launchpad for premier high impact life-sciences and biotech startups. Amgen entered into a multi-year platinum-level sponsorship with LabCentral in late 2014.



Amgen - Investors - RSS Content

Amgen Highlights Landmark Repatha® (Evolocumab) Cardiovascular Outcomes Study Amongst Data To Be Presented At ACC.17

Additional Presentations Include an Assessment of Repatha's Effect on Cognitive Function and Challenges Associated With Access to PCSK9 Inhibitor Therapy Late-Breaking Repatha Presentations Will be Webcast Live

Amgen - Investors - RSS Content

Amgen Presents New Data From Phase 3 XGEVA® (denosumab) Study In Multiple Myeloma Patients At The 16th International Myeloma Workshop

Amgen - Investors - RSS Content

Phase 3 Head-to-Head Trial Showed KYPROLIS® (Carfilzomib) Significantly Improved Overall Survival Compared To Velcade® (Bortezomib) In Relapsed Or Refractory Multiple Myeloma Patients

First-and-Only Head-to-Head Study Comparing Proteasome Inhibitors to Demonstrate Statistically Significant Improved Overall Survival Detailed Results Will be Presented at the 16th International Myeloma Workshop (IMW) in New Delhi

Amgen - Investors - RSS Content

FDA Approves Amgen's Parsabiv™ (Etelcalcetide), First New Treatment In More Than A Decade For Secondary Hyperparathyroidism In Adult Patients On Hemodialysis

Amgen - Investors - RSS Content

Amgen Announces Repatha® (Evolocumab) Significantly Reduced The Risk Of Cardiovascular Events In FOURIER Outcomes Study

Landmark Repatha Cardiovascular Outcomes Study Meets Primary and Key Secondary Endpoint Detailed Results to be Presented at ACC 66th Annual Scientific Session

Amgen - Investors - RSS Content